On the 10th and 11th of May collaborators and sponsors from FHI360 in the US visited WMRU for a 2-day training for the INNOVATE project:- A Phase 3, Open-Label, Multicenter Study to Evaluate Contraceptive Efficacy and Safety of Depot Medroxyprogesterone Acetate (150 mg/mL) Injected Subcutaneously Every Six Months. This project will be start next month.
